Evidence map›Paper›PMID 25840354›Full record

ReviewBiochimica et biophysica acta2016

Therapeutic potential of α-crystallin.

Ram H Nagaraj, Rooban B Nahomi, Niklaus H Mueller, Cibin T Raghavan, David A Ammar, J Mark Petrash

Open access · greenAbstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Small Heat Shock Proteins in Retinal Diseases.Frontiers in molecular biosciences · 2022
    Review
  9. Effect of Structural Changes Induced by Deletion ofInternational journal of molecular sciences · 2021
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ram H NagarajDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO 80045, USA. Electronic address: ram.nagaraj@ucdenver.edu.
Rooban B NahomiDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Niklaus H MuellerDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Cibin T RaghavanDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
David A AmmarDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
J Mark PetrashDepartment of Ophthalmology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
University of Colorado Denver · US

Funding

MOLECULAR BIOLOGY OF ALDOSE REDUCTASE AND CATARACTR01EY005856 · NEI · WASHINGTON UNIVERSITY · PI PETRASH, JONATHAN MARK · 1988 to 2014
$6.8M
Molecular Mechanisms of Protein Crosslinking in the LensR01EY023286 · NEI · UNIVERSITY OF COLORADO DENVER · PI NAGARAJ, RAM H · 2013 to 2022
$2.9M
Novel Therapeutics Against Diabetic Eye DiseaseR01EY021498 · NEI · UNIVERSITY OF COLORADO DENVER · PI LABARBERA, DANIEL V., PETRASH, JONATHAN MARK · 2011 to 2015
$2.1M
LENS CAPSULE AND SECONDARY CATARACTR01EY022061 · NEI · UNIVERSITY OF COLORADO DENVER · PI NAGARAJ, RAM H · 2013 to 2017
$1.9M
MOLECULAR STUDIES OF ALDOSE REDUCTASE AND CATARACTR23EY005856 · NEI · EMORY UNIVERSITY · PI PETRASH, JONATHAN MARK · 1985 to 1987
–
MOLECULAR BIOLOGY OF ALDOSE REDUCTASE AND CATARACTR55EY005856 · NEI · WASHINGTON UNIVERSITY · PI PETRASH, JONATHAN MARK · 1991 to 1991
–
NEI NIH HHS EY005856NEI NIH HHS EY021498NEI NIH HHS EY022061NEI NIH HHS EY023286NEI NIH HHS R01 EY005856NEI NIH HHS R01 EY021498NEI NIH HHS R01 EY022061NEI NIH HHS R01 EY023286
6 · The paper itself

Abstract

backgroundThe findings that α-crystallins are multi-functional proteins with diverse biological functions have generated considerable interest in understanding their role in health and disease. Recent studies have shown that chaperone peptides of α-crystallin could be delivered into cultured cells and in experimental animals with beneficial effects against protein aggregation, oxidation, inflammation and apoptosis. SCOPE OF REVIEW: In this review, we will summarize the latest developments on the therapeutic potential of α-crystallins and their functional peptides. MAJOR

conclusionsα-Crystallins and their functional peptides have shown significant favorable effects against several diseases. Their targeted delivery to tissues would be of great therapeutic benefit. However, α-crystallins can also function as disease-causing proteins. These seemingly contradictory functions must be carefully considered prior to their therapeutic use. GENERAL SIGNIFICANCE: αA and αB-Crystallin are members of the small heat shock protein family. These proteins exhibit molecular chaperone and anti-apoptotic activities. The core crystallin domain within these proteins is largely responsible for these prosperities. Recent studies have identified peptides within the crystallin domain of both α- and αB-crystallins with remarkable chaperone and anti-apoptotic activities. Administration of α-crystallin or their functional peptides has shown substantial inhibition of pathologies in several diseases. However, α-crystallins have been shown to promote disease-causing pathways. These two sides of the proteins are discussed in this review. This article is part of a Special Issue entitled Crystallin Biochemistry in Health and Disease.

Indexed as

alpha-CrystallinsAnimalsAntioxidantsBrain DiseasesEye DiseasesMolecular ChaperonesPeptidesProtein Aggregation, Pathologicalalpha-CrystallinsAntioxidantsMolecular ChaperonesPeptidesApoptosisChaperoneInflammationProtein aggregationTherapeutic potentialα-crystallin

Identifiers

PMID25840354
PMCPMC4591086
OpenAlexW1994650480

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.